Dycoxan 2,5 mg/ml belsoleges szuszpenzió juhoknak és szarvasmarháknak A.U.V. Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

dycoxan 2,5 mg/ml belsoleges szuszpenzió juhoknak és szarvasmarháknak a.u.v.

chanelle pharmaceuticals manufacturing ltd. - diklazuril - belsoleges szuszpenzió - diclazuril - szarvasmarha (borjú), juh (bárány)

Toviaz Európai Unió - magyar - EMA (European Medicines Agency)

toviaz

pfizer europe ma eeig - fezoterodin-fumarát - húgyhólyag, túlaktív - urológiai - a tünetek kezelése (fokozott húgyúti gyakoriság és / vagy sürgősség és / vagy sürgősségi inkontinencia), amelyek előfordulhatnak hiperaktív húgyhólyag szindrómában.

Imfinzi Európai Unió - magyar - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - karcinóma, nem kissejtes tüdő - daganatellenes szerek - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Imjudo Európai Unió - magyar - EMA (European Medicines Agency)

imjudo

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - daganatellenes szerek - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Edistride Európai Unió - magyar - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin-propándiol-monohidrát - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukorbetegségben szedett gyógyszerek - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. amellett, hogy egyéb gyógyszerekkel a kezelés a 2-es típusú cukorbetegség. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5. és 5. sz. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.